Using a reduced form binary econometric model, we analyze the determinants of pharmaceutical companies entry decisions into new submarkets. Our sample includes data for pharmaceutical companies over the period 1987-1998 for seven countries. Estimation is done both at the aggregate level and at a...

Transparency has become one of the primary themes in health care reform efforts in the United States and across the world. In the face of exorbitant drug prices, high levels of patient cost-sharing, and pharmaceutical expenditures that consume a growing proportion of public sector budgets, much...